Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis.

Muñoz-Vendrell A, Arroyo-Pereiro P, León I, Bau L, Matas E, Romero-Pinel L, Roca-Pereira S, Martínez-Yélamos A, Martínez-Yélamos S